Clinical Research Directory
Browse clinical research sites, groups, and studies.
Early Interferon-beta Treatment for West-Nile Virus Infection
Sponsor: Tel-Aviv Sourasky Medical Center
Summary
West Nile virus (WNV) is a mosquito-borne virus which in majority of cases causes only self-limited disease. Despite that, in minority of cases (\~0.5%) it can infect the brain and cause severe and even life-threatening disease (neuroinvasive disease). Recent study has shown that up to 40% of WNV patients who develop neuroinvasive disease, have antibodies against Interferons (anti-Type I interferon autoantibodies), which neutralizes interferons, and could explain the development of severe disease. The investigators therefore assume that early treatment with interferon beta (the type of interferon against which most patients do not have neutralizing antibodies) could prevent the development of severe neuroinvasive WNV disease.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
100
Start Date
2024-07-14
Completion Date
2025-12-31
Last Updated
2024-07-23
Healthy Volunteers
No
Conditions
Interventions
Rebif 44 MCG Per 0.5 ML Prefilled Syringe
Rebif 44mcg per 0.5ml administered subcutaneously
Saline
0.5mL of saline administered subcutaneously
Locations (1)
Tel-Aviv Sourasky Medical Center
Tel Aviv, Israel